All In Biotech

Drug Trial Radar · NCT05144997

Lorlatinib Continuation Study

LORLATINIB (PF-06463922) CONTINUATION PROTOCOL: AN OPEN-LABEL, SINGLE-ARM CONTINUATION STUDY FOR PARTICIPANTS WITH ALK-POSITIVE OR ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) CONTINUING FROM PFIZER SPONSORED LORLATINIB CLINICAL STUDIES

Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

76

Actual

Start

Dec 28, 2021

Primary completion

Oct 25, 2029

Study completion Oct 25, 2029

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Dec 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this protocol is to provide continued treatment access and safety follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer sponsored lorlatinib parent studies that will be closed. Additional follow-up safety data collection will permit further characterization of the safety profile of lorlatinib in participants continuing to receive study intervention

Conditions

  • Non-Small-Cell Lung Cancer
  • NSCLC

Interventions

  • LorlatinibDrug

    ALK-positive NSCL treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events leading to permanent discontinuation of study interventionTime frame: Baseline up to approximately 5 years
  2. Number of serious adverse events reported for all participantsTime frame: Baseline up to approximately 5 years

Locations

27 sites in 8 countries. Site status is shown where the registry gives one.

  • Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California

  • Fudan University Shanghai Cancer Center

    Shanghai, China

  • The First affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Beijing Chest Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China

  • Hunan Provincial Tumor Hospital

    Changsha, Hunan, China

  • General Hospital of Eastern Theater Command

    Nanjing, Jiangsu, China

  • Jilin Cancer Hospital

    Changchun, Jilin, China

  • The first hospital of jilin university

    Changchun, Jilin, China

  • Sir Run Shaw Hospital

    Hangzhou, Qiantang District, China

  • The Second Affiliated Hospital of PLA Air Force Medical University

    Xi'an, Shaanxi, China

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China

  • Sichuan Cancer hospital

    Chengdu, Sichuan, China

  • The First Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

  • The Second Affiliated Hospital of Zhejiang University College of Medicine

    Hangzhou, Zhejiang, China

  • CHU de Rennes - Hôpital Pontchaillou

    Rennes, France

  • Institut Gustave Roussy

    Villejuif, France

  • Healthcare Global Enterprises

    Bengaluru, Karnataka, India

  • Bhaktivedanta Hospital & Research Institute

    Thane, Maharashtra, India

  • Aichi Cancer Center Hospital

    Nagoya, Aichi-ken, Japan

  • National University Hospital

    Singapore, Singapore

  • National Cancer Centre Singapore

    Singapore, Singapore

  • Hospital Universitari Vall d'Hebron

    Barcelona, BARCELONA, Spain

  • National Taiwan University Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.